Abstract: Objective：To analyze the relationship between clinicopathological features and the expression levels of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-l) and prospero-related homeobox 1 (Prox-1) in endometrial carcinoma. Methods: Selected 57 cases of paraffin section specimens and 38 cases fresh tumor tissues and paracancer tissues of endometrial carcinoma. Immunohistochemistry, Western blotting, and Realtime RT-PCR were used to detect the expression of LYVE-1 and Prox-1 in tumor tissues and paracancer tissues. Analysis of the relationship between the expression of these two proteins and the clinicopathological features in tumor tissues and paracancer tissues. Results: ①Immunohistochemical display: The positive expression rate in tumor tissues of Prox-1 in the histologic grade I patients was statistically higher than that of grade Ⅱ and grade Ⅲ patients, the difference was statistically significant（P＜0.05）. The positive expression rate of LYVE-1 in the paracancer tissues of LVSI patients was statistically higher than that of those without LVSI（P＜0.05）. The positive expression rate of Prox-1 of LVSI and advanced patients increased in the paracancer tissues, compared with those without  LVSI and the early patients, the difference was statistically significant（P＜0.05）. ②Realtime RT-PCR and Western blotting detection: compared with the paracancer tissues without lymph node metastasis, the expression of Prox-1 protein in the lymph node metastasis group was 1.250 0±0.008 2（P＜0.05） and the expression of LYVE-1 protein was 1.860 0±0.012 4（P＜0.05）. Compared with that in the paracancer tissues, the expression level of Prox-1 mRNA in the tumor tissues in the lymph node metastasis group was 0.693+0.083（P＜0.05） and the expression level of LYVE-1 mRNA was 0.42±0.16（P＜0.05）. Conclusions: LYVE-1 and Prox-1 may be potential markers for lymph node metastasis in endometrial carcinoma. The results also suggest that the generation of lymphatic vessels in paracancer tissue is related to lymph node metastasis.

Key words: LYVE-1, Prox-1, Endometrial carcinoma, Clinicopathology, Blotting, portein, Polymerase chain reaction